文献速递妇科

CRABP2——高风险子宫内膜癌的新型生物标志物

CRABP2 - A novel biomarker for high-risk endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2022-09-24

研究探讨子宫内膜癌中CRABP2表达升高的临床与功能意义,按决策树分类器分为高、低表达组。TCGA中60例(11%)高表达、468例(89%)低表达,高表达与浆液性癌、总生存降低、晚期及高级别相关。RARG和RARA与CRABP2相关且在浆液性癌中与更差预后相关。

要点

  • TCGA中60例(11%)CRABP2高表达,468例(89%)低表达。
  • 高表达与浆液性子宫内膜癌、总生存降低、晚期及高级别相关。
  • RARG和RARA与CRABP2表达相关,在浆液性癌中与更差预后相关。

核心结论

  • CRABP2表达与不良预后及晚期子宫内膜癌相关。
  • RARA和RARG表达与CRABP2相关,并在晚期组织学亚型中与更差预后相关。
  • Polycomb靶基因集及两个主调控因子ELP3和BMP7被识别为驱动CRABP2异常表达的功能相关机制。

研究设计与样本

  • 研究纳入子宫内膜癌患者,使用决策树分类器分为CRABP2高表达组和低表达组。
  • 采用单变量和多变量统计分析确定CRABP2表达升高的预后和临床病理意义。
  • 通过差异表达分析生成CRABP2基因签名,并用基于网络的方法分析。
  • 结果在临床蛋白质组肿瘤分析联盟(CPTAC)、新生成的120例子宫内膜组织队列和癌症依赖图谱(DepMap)中验证。

主要发现

  • TCGA中60例(11%)患者CRABP2高表达,468例(89%)低表达。
  • 高表达与浆液性子宫内膜癌、总生存降低、晚期和高级别相关。
  • 下游视黄酸受体RARG和RARA与CRABP2表达相关,并在浆液性子宫内膜癌中与更差预后相关。
  • CRABP2基因签名富集Polycomb靶基因集,并受ELP3和BMP7调控。
  • BMP7表达在CRABP2高表达组升高,与更差预后相关;CRISPR-Cas9筛选显示基因敲除后其细胞适应度评分与CRABP2相关,ELP3则相反,提示两个主调控因子作用相反。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Investigate the clinical and functional implications of elevated CRABP2 expression in endometrial cancer (EC) patients. METHODS: Patients were stratified into high and low CRABP2 expression groups using a decision tree classifier. Univariate and multivariate statistical analyses determined the prognostic and clinicopathological consequences of increased CRABP2 expression. A CRABP2 gene signature was generated using differential expression analysis, and analyzed using network-based approaches. The findings were validated in The Clinical Proteomic Tumor Analysis Consortium (CPTAC), a newly generated cohort of 120 endometrial tissues, and The Cancer Dependency Map (DepMap). RESULTS: 60 (11%) patients in TCGA had high CRABP2 expression, whilst 468 (89%) had low expression. High expression was associated with serous EC, reduced overall survival, advanced stage and grade. Downstream retinoic acid receptors (RARG and RARA) were correlated with CRABP2 expression and were associated with worse prognosis in serous EC. The CRABP2 gene signature was enriched for Polycomb target gene sets, and was regulated by ELP3 and BMP7. BMP7 expression was increased in the CRABP2-high group, was associated with worse prognosis, and CRISPR-Cas9 screens revealed correlations in its cell-fitness score with CRABP2 following gene knockout. The opposite was true for ELP3, suggesting opposing effects from both master regulators. CONCLUSIONS: CRABP2 expression is associated with poor prognosis and advanced EC. The expression of RARA and RARG correlates with CRABP2 and are associated with worse prognosis in advanced histological subtypes. Polycomb target gene sets and two master regulators, ELP3 and BMP7, were identified as functionally relevant mechanisms driving aberrant CRABP2 expression.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Egan D, Moran B, Wilkinson M, et al. CRABP2 - A novel biomarker for high-risk endometrial cancer. Gynecol Oncol. 2022. PMID: 36163055. doi:10.1016/j.ygyno.2022.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。